Education
About Us
Working with TipRanks
Follow Us
Protagenic Therapeutics (PTIX)
NASDAQ:PTIX
RESEARCH TOOLSreports
Total Valuation
Protagenic Therapeutics has a market cap or net worth of $2.26M. The enterprise value is $5.34M.
Market Cap$2.26M
Enterprise Value$5.34M
Share Statistics
Protagenic Therapeutics has 7.53M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding7.53M
Owned by Insiders6.29%
Owned by Instutions0.25%
Financial Efficiency
Protagenic Therapeutics’s return on equity (ROE) is -1.36 and return on invested capital (ROIC) is -123.41%.
Return on Equity (ROE)-136.32%
Return on Assets (ROA)-115.66%
Return on Invested Capital (ROIC)-123.41%
Return on Capital Employed (ROCE)-123.41%
Revenue Per Employee$28,343
Profits Per Employee-$5,647,785
Employee Count1
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Protagenic Therapeutics is -0.86. Protagenic Therapeutics’s PEG ratio is -0.02.
PE Ratio-0.86
PS Ratio0.00
PB Ratio1.17
Price to Fair Value1.17
Price to FCF-1.12
Price to Operating Cash Flow-1.16
PEG Ratio-0.02
Income Statement
In the last 12 months, Protagenic Therapeutics had revenue of $28.34K and earned -$5.65M in profits. Earnings per share was -$1.27.
Revenue$28.34K
Gross Profit-$23.42K
Operating Income-$5.27M
Pretax Income-$5.65M
Net Income-$5.65M
EBITDA-5.56M
Earnings Per Share (EPS)-1.27
Cash Flow
In the last 12 months, operating cash flow was -$4.54M and capital expenditures -$93.97K, giving a free cash flow of -$4.64M billion.
Operating Cash Flow-$4.54M
Free Cash Flow-$4.64M
Free Cash Flow per Share-$0.62
Dividends & Yields
Protagenic Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-89.59%
Earnings Yield-116.26%
Stock Price Statistics
Beta-1.78
52-Week Price Change-77.04%
50-Day Moving Average0.28
200-Day Moving Average0.54
Relative Strength Index (RSI)52.53
Average Volume (3m)10.54M
Important Dates
Protagenic Therapeutics upcoming earnings date is Apr 1, 2024, Before Open.
Last Earnings DateNov 16, 2021
Next Earnings DateApr 1, 2024
Ex-Dividend Date―
Financial Position
Protagenic Therapeutics as a current ratio of 6.41, with Debt / Equity ratio of 0.00
Current Ratio6.41
Quick Ratio6.41
Debt to Market Cap0.00
Net Debt to EBITDA0.29
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Protagenic Therapeutics has paid $0.00 in taxes.
Income Tax$0.00
Effective Tax Rate0.00%
Enterprise Valuation
Protagenic Therapeutics EV to EBITDA ratio is -0.67, with an EV/FCF ratio of -0.78.
EV to Sales0.00
EV to EBITDA-0.67
EV to Free Cash Flow-0.78
EV to Operating Cash Flow-0.81
Balance Sheet
Protagenic Therapeutics has $1.06M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$1.06M billion.
Cash & Marketable Securities$1.06M
Total Debt$0.00
Net Cash-$1.06M
Net Cash Per Share-$0.14
Tangible Book Value Per Share$0.84
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Protagenic Therapeutics is , which is 11.43% higher than the current price. The consensus rating is
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast-40.51%